Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) – Sanofi EFC18156

If You’re Navigating Life With CIDP, This Study May Offer a New Option 

Helping adults with CIDP explore potential new options through clinical research. 

Profound Research is enrolling a Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) study that is assessing an investigational medication to see if it helps improve functional disability. 

To be eligible to participate, you must: 

• Be at least 18 years of age 

• Be diagnosed or possibly have CIDP 

• Be taking intravenous Immunoglobulin 

• Have evidence of at least 1 deterioration event in the last 2 years of 2 events in the last 5 years 

• Have an INCAT score of 2-9 

• Not have Guillain-Barré syndrome or diabetic neuropathy   

Additional criteria apply. 

Qualified participants will receive: 

• Study-related care and study medication at no cost 

• Financial compensation for time and travel expenses 

Number of visits and duration of study: 

• 17 clinic visits over 48 weeks and 5 additional phone call visits

Call us at 725-226-5989 or complete the form and our team will reach out soon to help determine your eligibility.